Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Forodesine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Forodesine SCHEMBL15740309 | 1.00 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL21386033 | 1.00 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL15740194 | 1.00 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL15318145 | 1.00 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL15373311 | 1.00 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL3896676 | 1.00 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL15525350 | 0.99 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL15718038 | 0.99 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL17161840 | 0.99 | PNP (1.00) | PNPHPRT1 | |
| Forodesine SCHEMBL17162006 | 0.99 | PNP (1.00) | PNPHPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3010340-A2 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE, ENHANCING IMMUNOTHERAPY, AND INCREASING VACCINE POTENCY | Nitor Therapeutics (US) | 2016-04-27 | — | — | EP | claimed |
| WO-2014205199-A2 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE, ENHANCING IMMUNOTHERAPY, AND INCREASING VACCINE POTENCY | NITOR THERAPEUTICS (US) | 2014-12-24 | — | — | WO | claimed |
| EP-2343074-A1 | Use of purine analogues for treating airway diseases | Merck Serono S.A. (CH) | 2011-07-13 | — | — | EP | claimed |
| US-20230271970-A1 | METHOD FOR PREPARING FORODESINE | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-4190785-A1 | METHOD FOR PREPARING FORODESINE | Sichuan University (CN) | 2023-06-07 | — | — | EP | disclosed |
| EP-2343074-A1 | Use of purine analogues for treating airway diseases | Merck Serono S.A. (CH) | 2011-07-13 | — | — | EP | disclosed |
| US-7405297-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-07-29 | — | — | US | disclosed |
| US-7405297-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-07-29 | — | — | US | disclosed |
| US-7390890-B2 | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390890-B2 | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070197561-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197561-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070161667-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070161667-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-7211653-B2 | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211653-B2 | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2007-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271970-A1 | METHOD FOR PREPARING FORODESINE | F7, CYP3A7, CYP7A1 | PNP 860/4885HPRT1 709/4885 |
| US-20070197561-A1 | Inhibitors of nucleoside metabolism | CFH, CBR3, SLCO2B1 | PNP 35/4885HPRT1 124/4885 |
| US-20070161667-A1 | Process for preparing inhibitors of nucleoside metabolism | PNP, UGT1A3, AGL | PNP 1/4885HPRT1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.